The continuous overhang of geopolitical events is keeping the trends suppressed, as the global cues still have a very deep overhang, leading to market confusion. As the trends ahead show that clarity ...

Opportunities in traditional pharma companies with a focus on domestic formulations and US generic drugs are drying up ...

Most of Wall Street piled into the Magnificent Seven stocks in the past few years, and although a lot of that flow has ...

VYN201 shows promise for vitiligo with once-daily dosing & potential safety benefits, competing with OPZELURA.

Zurich Insurance offers a 5% yield and solid growth, but high valuation and rising risks limit upside. Click here to read an ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

The data mining and artificial intelligence (AI) specialist is firing on all cylinders, but the answer is still complicated.

Investors are hopeful a potential trade deal between the U.S. and European Union could bring more certainty to markets ahead ...

UK equities are staging a comeback, but there’s still plenty of value out there, says Rupert Hargreaves UK equities are ...

Small-cap stocks might finally be ready to shine in 2025, thanks to policy shifts and bullish signals. ETFs like IWM, DEEP, ...

Tuya Inc. (NYSE: TUYA) is one of the High Growth Penny Stocks That Are Profitable in 2025. On May 23, Tuya Inc. (NYSE:TUYA) ...